Coronavirus Notebook: Regeneron, HHS To Develop Antibody

China Domestics Step Up R&D Efforts

Wuhan Institute of Pathology files patent over new use of Gilead's remdesivir and Regeneron expands collaboration with HHS to include 2019-nCoV.  

LARGELY EMPTY STREETS IN BEIJING AS HOLIDAY PROLONGED FOR ANOTHER WEEK
STREETS LARGELY EMPTY AS BEIJING, 22 PROVINCES EXTEND HOLIDAY • Source: Brian Yang

New forces are joining in the battle against the new coronavirus outbreak. Regeneron Pharmaceuticals Inc. and the US Department of Health and Human Services (HHS) are expanding a collaboration to include 2019-nCoV, given that Regeneron’s REGN-EB3 has demonstrated effectiveness against the Ebola virus.

REGN-EB3, an combination therapy comprising three antibodies, has been granted US Breakthrough Therapy designation and Regeneron has filed a rolling...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from China

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from Focus On Asia